Considerations for environmental sustainability in clinical trials: A case study simulation of the Re-Evaluating the Inhibition of Stress Erosions (REVISE) trial
Authors' conclusion
This simulation demonstrates that enabling transition from intravenous pantoprazole to enteral lansoprazole may have yielded substantial reductions in both greenhouse gas emissions and costs.
Study context
- Population
- REVISE trial (IV pantoprazole or placebo; median IV duration 5 days)
- Comparison
- Simulated IV pantoprazole with step-down to enteral lansoprazole on day 2 vs 5-day IV pantoprazole
- Primary endpoint
- Carbon emission (greenhouse gas emissions from intervention and waste) and monetary impact
Methodological detailssecondary analysis of the REVISE randomised trial, Emissions estimated with cost-based factors for drugs and weight-based factors for waste; costs from average acquisition costs of REVISE centres
- Secondary analysis of the REVISE randomised trial
- Emissions estimated with cost-based factors for drugs and weight-based factors for waste; costs from average acquisition costs of REVISE centres
Primary result
As reported in the abstract
Greenhouse gas emissions per average 5-day course
Reduction
28%
By group
Further findings
Emissions and drug-related costs, entire trial
- Emissions saved with IV/enteral intervention (approximately)
- 9000 kgCO2e
- Drug-related costs (acquisition, preparation, administration supplies) halved
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Considerations for environmental sustainability in clinical trials: A case study simulation of the REVISE trial. J Crit Care. Published 24 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →